Methods of treatment with an iboga alkaloid

Patent metadata

Field	Value
Publication number	US-12396997-B2
Application number	US-202418817153-A
Country	US
Kind code	B2
Filing date	Aug 27, 2024
Priority date	Sep 14, 2022
Publication date	Aug 26, 2025
Grant date	Aug 26, 2025

Abstract

Methods for treating a neuropsychiatric disorder by administering an iboga alkaloid and a cardioprotective agent in conjunction with analysis of brain image data is described. Also described are methods to improve brain health and to slow or reverse brain aging by disorder by administering an iboga alkaloid and a cardioprotective agent, where analysis of brain image data is used to monitor and/or evaluate treatment effectiveness.

First claim

It is claimed:

1. A method for treating a neuropsychiatric condition selected from traumatic brain injury and post-traumatic stress disorder in a subject, comprising:
administering, or instructing to administer, to a subject a cardioprotective agent in an amount effective to achieve a physiologic effect to reduce risk of long QT syndrome and an iboga alkaloid or salt thereof, wherein the cardioprotective agent is a magnesium salt and the iboga alkaloid is ibogaine; and
monitoring the subject by analyzing image data from a brain image to determine a predicted brain age.

2. The method of claim 1 , further comprising based on said monitoring, continuing said administering or instructing to administer or recommending an alternative to said administering or instructing to administer.

3. The method of claim 1 , wherein the subject has a chronological age, the method further comprising comparing the predicted brain age to the chronological age.

4. The method of claim 3 , further comprising repeating said administering or instructing to administer if the predicted brain age is greater than the chronological age.

5. The method of claim 4 , further comprising repeating said monitoring to determine a post-treatment predicted brain age, and comparing said post-treatment predicted brain age to the chronological age.

6. The method of claim 5 , further comprising repeating said administering or instructing to administer if the post-treatment predicted brain age is greater than the chronological age.

7. The method of claim 5 , further comprising repeating said administering or instructing to administer if the post-treatment predicted brain age is equal to or less than the precited brain age.

8. The method of claim 5 , further comprising recommending an alternative to said administering or instructing to administer if the post-treatment predicted brain age is equal to or greater than the predicted brain age.

9. A method for treating a neuropsychiatric condition selected from traumatic brain injury and post-traumatic stress disorder in a subject, comprising:
analyzing a first image data of a subject's brain using a brain age model to determine a first estimated brain age of the brain, where the first image data is captured prior to administration of an iboga alkaloid or salt thereof;
administering, or instructing to administer, to the subject a cardioprotective agent in an amount effective to achieve a physiologic effect to reduce risk of long QT syndrome and the iboga alkaloid or salt thereof;
analyzing a second image data of the subject's brain using the brain age model to determine a second estimated brain age of the brain, where the second image data is captured after administration of the iboga alkaloid or salt thereof; and
verifying treatment efficacy when the first estimated brain age is greater than the second estimated brain age,
wherein the iboga alkaloid is ibogaine and the cardioprotective agent is a magnesium salt.

10. The method of claim 9 , wherein verifying treatment efficacy comprises verifying a correct dosage amount.

11. The method of claim 9 , further comprising administering, or instructing to administer, to the subject an additional dose of the cardioprotective agent in an amount effective to achieve a physiologic effect to reduce risk of long QT syndrome and the iboga alkaloid or salt thereof.

12. The method of claim 1 , wherein the neuropsychiatric condition is traumatic brain injury.

13. The method of claim 1 , wherein the neuropsychiatric condition is post-traumatic stress disorder.

Assignees

• Univ Leland Stanford Junior
• Soneira Inc P B C

Inventors

• Williams Nolan R
• Coetzee John Philip
• Geoly Andrew Dedinas
• Daniels Annamarie
• Bird Gregory

Classifications

• A61B5/4064

  Evaluating the brain (for intracranial pressure A61B5/031; for cerebral blood gases A61B5/14553; using EEG A61B5/369) · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61P9/06 Primary

  Antiarrhythmics · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title